Format

Send to

Choose Destination
Int J Cancer. 2015 Oct 15;137(8):1890-900. doi: 10.1002/ijc.29568. Epub 2015 Apr 29.

Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma.

Author information

1
Department of Biopathology, Institut Curie, Paris, France.
2
EA4340-BCOH, Versailles Saint-Quentin-en-Yvelines University, Guyancourt, France.
3
Department of Translational Research, Institut Curie, Paris, France.
4
Bioinformatics and Computational Systems Biology of Cancer, Institut Curie, Paris, France.
5
Mines Paris Tech, Paris, France.
6
Inserm U900, Paris, France.
7
Inserm U830 Institut Curie, Paris, France.
8
Department of Medical Oncology, Institut Curie, Paris, France.
9
Department of Surgery, and on behalf of the Gynecologic Study Group, Institut Curie, Paris, France.
10
CNRS UMR 144.
11
Université Paris Descartes, Sciences Pharmaceutiques et Biologiques, Sorbonne Paris Cité, Paris, France.

Abstract

The treatment of epithelial ovarian cancer (EOC) is narrowly focused despite the heterogeneity of this disease in which outcomes remain poor. To stratify EOC patients for targeted therapy, we developed an approach integrating expression and genomic analyses including the BRCAness status. Gene expression and genomic profiling were used to identify genes recurrently (>5%) amplified and overexpressed in 105 EOC. The LST (Large-scale State Transition) genomic signature of BRCAness was applied to define molecular subgroups of EOC. Amplified/overexpressed genes clustered mainly in 3q, 8q, 19p and 19q. These changes were generally found mutually exclusive. In the 85 patients for which the genomic signature could be determined, genomic BRCAness was found in 52 cases (61.1%) and non-BRCAness in 33 (38.8%). A striking mutual exclusivity was observed between BRCAness and amplification/overexpression data. Whereas 3q and 8q alterations were preferentially observed in BRCAness EOC, most alterations on chromosome 19 were in non-BRCAness cases. CCNE1 (19q12) and BRD4 (19p13.1) amplification/overexpression was found in 19/33 (57.5%) of non-BRCAness cases. Such disequilibrium was also found in the TCGA EOC data set used for validation. Potential target genes are frequently amplified/overexpressed in non-BRCAness EOC. We report that BRD4, already identified as a target in several tumor models, is a new potential target in high grade non-BRCAness ovarian carcinoma.

KEYWORDS:

BRCAness; BRD4; CCNE1; genomics; ovarian cancer

PMID:
25892415
DOI:
10.1002/ijc.29568
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center